Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?
Sep 19
AKUS Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
AKUS Community Narratives
There are no narratives available yet.
Akouos, Inc. Key Details
Last Reported Earnings
Sep 30, 2022
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.51
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Akouos, Inc. Competitors
Snowflake Analysis
About AKUS
- Founded
- 2016
- Employees
- 103
- CEO
- WebsiteView website
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Market Insight
The number of IPOs and the capital raised this year are on track to outpace the last three years combined. And the thing is, successful IPOs attract more IPOs. Some will be genuine gems, while others, not so much. That’s why this week, we’re digging into the IPO market, and more importantly, how you can improve your odds of spotting a winner.
Continue reading
U.S. Market Performance
- 7 Days: -0.6%
- 3 Months: 8.7%
- 1 Year: 18.1%
- Year to Date: 9.7%
The Communication Services sector gained 3.6% while the market remained flat over the last week. More promisingly, the market is up 18% over the past year. Earnings are forecast to grow by 15% annually. Market details ›